CompletedNCT00937846

Brain uptake of GSK1034702 measured with PET imaging

About this title

Medication studyAges 35–55United KingdomSchizophrenia

The study in practice

Understand this study

This study was for healthy volunteers. Listed age limits: 35 years to 55 years. Other eligibility criteria applied.

Listed locations: London and 1 more locationSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateStarted: July 15, 2009

Recruitment status: Completed
Enrollment listed in the registry: 4
Sponsor: GlaxoSmithKline
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Drug
Study phase: Phase 1
Locations: United Kingdom
Age range: From 35 Years to 55 Years
Official registry ID: NCT00937846
Official title: Show the full official title
An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [Carbonyl-11C] GSK1034702 in Healthy Subjects

Completed

London

FAQ

Who is behind this study?

The study sponsor is GlaxoSmithKline.

Did this study involve medication?

Yes. The study involved medication, including GSK1034702.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 35 years to 55 years. Other eligibility criteria applied.